2025-08-13
InnoStar successfully assisted NEUREGEN's Groundbreking Glioblastoma Therapy in IND Enabling
August 11, 2025: NEUREGEN's NRG-103, the world's first in situ transdifferentiation-based gene therapy for glioblastoma, received FDA IND approval, with non-clinical support from InnoStar aiding the approval.
See more
